Overview

Pharmacokinetics and Safety of AmBisome and DKF-5122

Status:
Completed
Trial end date:
2022-01-28
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the Safety and Pharmacokinetic Characteristics of AmBisome and DKF-5122
Phase:
Phase 1
Details
Lead Sponsor:
Dongkook Pharmaceutical Co., Ltd.
Treatments:
Liposomal amphotericin B